News | Heart Valve Technology | March 07, 2019

Transcatheter Pulmonary Valve Therapy Market Poised for Growth

Increasing cardiovascular disease prevalence across the globe coupled with ongoing research and development expected to stimulate market growth

Transcatheter Pulmonary Valve Therapy Market Poised for Growth

March 7, 2019 — Rising incidence of congenital heart disease and increasing awareness of transcatheter pulmonary valve (TPV) therapy is expected to drive growth in the TPV market, according to Reports and Data, reaching a value of $66.4 million by 2026.

Transcatheter pulmonary valve therapy has come up as the treatment of choice in most congenital heart disease patients with degeneration of a previous right ventricular outflow tract repair. To avoid the need for repeat median sternotomy procedures, less invasive catheter-based interventions to treat pulmonary valve dysfunction have been developed over time.

In the United States, the incidence of congenital heart defects ranges between four to 10 cases per 1,000, clustering around 8 cases per 1,000 live births. Continental variations in birth prevalence have been observed, from about 6.9 cases per 1,000 births in Europe to 9.3 cases per 1,000 births in Asia. However, the relationship between valve size and balloon waist may reflect selection and procedural bias, which is likely to hinder the market growth

Further key findings from the report suggest

  • The TPV therapy market is rising at a high growth rate of 7.2 percent in Asia Pacific followed by North America and Europe. High incidence of cardiovascular diseases will drive the demand for the market during forecast period across all regions;

  • The valuation for balloon-expanded transcatheter valve market was $30.5 million in 2017 and is expected to grow to $53 million by 2026.

  • Asia Pacific is expected to witness a CAGR of 12.9 percent in the forecast period. Emerging markets such China and Japan are likely to witness high growth; and

  • Regional reimbursement scenarios are another key regulatory factor for adoption and growth of transcatheter pulmonary valve therapy in the region.

Key participants discussed in the report include Medtronic, Edward Lifesciences, Cryolife Inc. and Venus Medtech.

For more information: www.reportsanddata.com


Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now